THC vs. CBD: Clinical Differences, Mechanisms, and What Research Recommends

THC and CBD are the two most studied cannabinoids in Cannabis sativa, but their pharmacology, clinical applications, and risk profiles differ dramatically. Understanding the distinction is foundational to interpreting cannabis research and making informed choices about product selection.

Mechanism of Action

THC (delta-9-tetrahydrocannabinol) is a partial agonist at CB1 and CB2 receptors — it binds directly to these receptors and activates them, producing the psychoactive effects, analgesia, appetite stimulation, and antiemetic effects for which it is best known. CB1 receptors are densely expressed in the cortex, hippocampus, basal ganglia, and cerebellum, explaining THC's broad psychoactive footprint.

CBD (cannabidiol) does not bind significantly to CB1 or CB2 receptors. Instead, it acts as a negative allosteric modulator of CB1 receptors — it doesn't activate them but changes their shape, reducing their response to THC. This is the molecular basis for CBD's ability to attenuate THC-induced anxiety and psychosis risk. CBD also acts on TRPV1 (the capsaicin receptor), serotonin 5-HT1A receptors, GPR55, and multiple ion channels, giving it a broader and more complex pharmacological profile than often described.

Clinical Evidence Comparison

THC has the stronger evidence base for pain, particularly neuropathic pain, appetite stimulation in cancer and HIV wasting, and nausea suppression. It is the primary active component in FDA-approved dronabinol (Marinol).

CBD has the strongest evidence for epilepsy — it is the basis for the only FDA-approved plant-derived cannabis medicine, Epidiolex, approved for Dravet syndrome and Lennox-Gastaut syndrome. Evidence for CBD in anxiety disorders is promising but based on smaller trials.